Evidence map›Paper›PMID 33951271›Full record

ArticleAging cell2021

Gain of PITRM1 peptidase in cortical neurons affords protection of mitochondrial and synaptic function in an advanced age mouse model of Alzheimer's disease.

Fang Du, Qing Yu, Shijun Yan, Zhihua Zhang, Jhansi Rani Vangavaragu, Doris Chen, Shi Fang Yan, Shirley ShiDu Yan

Open access · goldAbstract read
In one paragraph

Article in Aging cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fang DuDepartment of Surgery, Columbia University, New York, NY, USA.
Qing YuDepartment of Surgery, Columbia University, New York, NY, USA.
Shijun YanDepartment of Pharmacology and Toxicology and Higuchi bioscience Center, University of Kansas, Lawrence, KS, USA.
Zhihua ZhangDepartment of Pharmacology and Toxicology and Higuchi bioscience Center, University of Kansas, Lawrence, KS, USA.
Jhansi Rani VangavaraguDepartment of Pharmacology and Toxicology and Higuchi bioscience Center, University of Kansas, Lawrence, KS, USA.
Doris ChenDepartment of Pharmacology and Toxicology and Higuchi bioscience Center, University of Kansas, Lawrence, KS, USA.
Shi Fang YanDepartment of Surgery, Columbia University, New York, NY, USA.ORCID 0000-0002-2597-8967
Shirley ShiDu YanDepartment of Surgery, Columbia University, New York, NY, USA.
University of Kansas · USColumbia University · US

Funding

Role of Cyclophilin D in Abeta-induced synaptic injuryR37AG037319 · NIA · UNIVERSITY OF KANSAS LAWRENCE · PI YAN, SHIRLEY SHIDU · 2010 to 2019
$3.1M
Mitochondria modulate Tau pathology and neuroinflammationR01AG069426 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI YAN, SHIRLEY SHIDU · 2020 to 2024
$3.0M
RAGE, mitochondria, and tau pathology in ADR01AG061324 · NIA · UNIVERSITY OF KANSAS LAWRENCE · PI YAN, SHI FANG · 2019 to 2023
$2.9M
Pink1, amyloid pathology, and mitochondrial quality control in Alzheimer's DiseaseRF1AG054320 · NIA · UNIVERSITY OF KANSAS LAWRENCE · PI YAN, SHIRLEY SHIDU · 2018 to 2018
$2.8M
TOMM40-mediated mitochondrial dysfunction and Alzheimers diseaseR01AG053041 · NIA · UNIVERSITY OF KANSAS LAWRENCE · PI YAN, SHIRLEY SHIDU · 2017 to 2021
$2.7M
Mitochondrial degrading enzyme, synaptic mitochondrial function in AD mouse modelR01AG044793 · NIA · UNIVERSITY OF KANSAS LAWRENCE · PI YAN, SHIRLEY SHIDU · 2014 to 2018
$1.9M
Glyoxalase-1, amyloid pathology, mitochondrial and synaptic injury in ADR56AG064934 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI YAN, SHIRLEY SHIDU · 2019 to 2019
$616k
TOMM40-mediated mitochondrial dysfunction and Alzheimers diseaseR56AG053041 · NIA · UNIVERSITY OF KANSAS LAWRENCE · PI YAN, SHIRLEY SHIDU · 2016 to 2016
$387k
NIA NIH HHS R01 AG044793NIA NIH HHS R01 AG053041NIA NIH HHS R01 AG061324NIA NIH HHS R01 AG069426NIA NIH HHS R37 AG037319NIA NIH HHS R56 AG053041NIA NIH HHS R56 AG064934NIA NIH HHS RF1 AG054320
6 · The paper itself

Abstract

Mitochondrial dysfunction is one of the early pathological features of Alzheimer's disease (AD). Accumulation of cerebral and mitochondrial Aβ links to mitochondrial and synaptic toxicity. We have previously demonstrated the mechanism by which presequence peptidase (PITRM1)-mediated clearance of mitochondrial Aβ contributes to mitochondrial and cerebral amyloid pathology and mitochondrial and synaptic stress in adult transgenic AD mice overexpressing Aβ up to 12 months old. Here, we investigate the effect of PITRM1 in an advanced age AD mouse model (up to 19-24 months) to address the fundamental unexplored question of whether restoration/gain of PITRM1 function protects against mitochondrial and synaptic dysfunction associated with Aβ accumulation and whether this protection is maintained even at later ages featuring profound amyloid pathology and synaptic failure. Using newly developed aged PITRM1/Aβ-producing AD mice, we first uncovered reduction in PITRM1 expression in AD-affected cortex of AD mice at 19-24 months of age. Increasing neuronal PITRM1 activity/expression re-established mitochondrial respiration, suppressed reactive oxygen species, improved synaptic function, and reduced loss of synapses even at advanced ages (up to 19-24 months). Notably, loss of PITRM1 proteolytic activity resulted in Aβ accumulation and failure to rescue mitochondrial and synaptic function, suggesting that PITRM1 activity is required for the degradation and clearance of mitochondrial Aβ and Aβ deposition. These data indicate that augmenting PITRM1 function results in persistent life-long protection against Aβ toxicity in an AD mouse model. Therefore, augmenting PITRM1 function may enhance Aβ clearance in mitochondria, thereby maintaining mitochondrial integrity and ultimately slowing the progression of AD.

Indexed as

AgingAlzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBrainCognitionDisease Models, AnimalFemaleInflammationMaleMetalloendopeptidasesMice, TransgenicMitochondriaNeuronsSynapsesAmyloid beta-PeptidesAmyloid beta-Protein PrecursorMetalloendopeptidasesPITRM1 protein, humanamyloid pathologymitochondrial Aβ clearancemitochondrial proteolysismitochondria-related proinflammationsynaptic rescue

Identifiers

PMID33951271
PMCPMC8135081
OpenAlexW3158045691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.